logo Hematology/Oncology Research Studies: Open for Enrollment Date: 10/22/18

Category: STEM CELL TRANSPLANTATION AND CELLULAR THERAPY

Allogeneic Stem Cell Transplantation of CordIn (Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells) in Patients with Hemoglobinopathies

NCT#/Phase: NCT02504619
Phase 1/2
IRB#: 2015-029
Description: Ex Vivo expanded unrelated donor umbilical cord blood transplant protocol for patients with severe sickle cell or transfusion dependent thalassemia. CordIn is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells. The overall study objectives are to evaluate the safety and efficacy of CordIn.
Inclusion: Individuals who are 2-25 years old with severe sickle cell or transfusion dependent thalassemia. who are medically suitable for transplant who do not have an identified matched sibling or fully matched unrelated donor with an identified suitably matched unrelated donor cord blood unit.
Enrollment Status: Open for enrollment
Sponsor: Gamida Cell Ltd
Principal Investigator(s): Mark Walters, MD
Contact(s): Marci Moriarty, RN (510-428-3385 x5396)
Julie Decaris (510-428-3385 x2739)
Study Link: https://clinicaltrials.gov/ct2/show/NCT02504619

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000